ライフサイエンスコーパス: oxygen therapy

1 ty at presentation (as defined by hypoxia or oxygen therapy).

2 tensive care unit/critical care unit, and/or oxygen therapy).

3 ation period when compared with conventional oxygen therapy.

4 ith rectal bleeding, benefit from hyperbaric oxygen therapy.

5 roves oxygenation compared with conventional oxygen therapy.

6 eived high-flow therapy and 263 conventional oxygen therapy.

7 d hypoxaemia compared with standard low-flow oxygen therapy.

8 ow oxygen therapy, and 79 (35%) to high-flow oxygen therapy.

9 herapy, and ten (13%) had received high-flow oxygen therapy.

10 in the ICU to receive conservative or usual oxygen therapy.

11 ildhood pneumonia and hypoxaemia is low-flow oxygen therapy.

12 ts meet current specifications for long-term oxygen therapy.

13 s of conventional compared with conservative oxygen therapy.

14 ry rehabilitation programs, and supplemental oxygen therapy.

15 ing illness who are ineligible for long-term oxygen therapy.

16 correlated with the duration of supplemental-oxygen therapy.

17 were discharged on tube feedings and 22% on oxygen therapy.

18 anent mechanical ventilation or supplemental oxygen therapy.

19 ion to the hospital, and 24 had been on home oxygen therapy.

20 hanical ventilatory support and supplemental oxygen therapy.

21 py, and with oxygen therapy compared with no oxygen therapy.

22 development and healing of lungs injured by oxygen therapy.

23 esumption of normal feeding--and duration of oxygen therapy.

24 strategy of HFNO compared with conventional oxygen therapy.

25 recovery compared with conventional low-flow oxygen therapy.

26 atio in the management of patients requiring oxygen therapy.

27 oint of contact and referral for appropriate oxygen therapy.

28 nt clinical approaches, including hyperbaric oxygen therapy.

29 aemia compared with use of standard low-flow oxygen therapy.

30 ngth of hospital stay compared with standard oxygen therapy.

31 Hg higher), when compared with conventional oxygen therapy.

32 dency on mechanical ventilation or high-flow oxygen therapy.

33 mmendations, such as variable thresholds for oxygen therapy.

34 itoring, and discontinuation of supplemental oxygen therapy.

35 ed with either standard oxygen and high-flow oxygen therapy.

36 ompared with standard low-flow and high-flow oxygen therapies.

37 D-19-specific therapy (0.22 [0.15-0.34]) and oxygen therapy (0.24 [0.14-0.43]) than did those diagnos

38 28 255 [17.4%] aged 61-70 years), hyperbaric oxygen therapy; 15 916 (7126 [44.8%] aged 41-50 years),

39 d in 87 of 414 patients with high-flow nasal oxygen therapy (21.0%) and 91 of 416 patients with BiPAP

40 ventilation-free days compared with standard oxygen therapy (25.4 vs 23.2 days; absolute difference,

41 female sex, 56.9%) were assigned to standard oxygen therapy (367 patients), CPAP (346 patients), or N

42 ith BiPAP [5.5%] and 28 with high-flow nasal oxygen therapy [6.8%]; P = .66) (absolute difference, 1.

43 re respiratory support (55 [40] vs 54 [42]), oxygen therapy (88 [41] vs 91 [59]), and hospitalization

44 ortality between patients receiving standard oxygen therapy (9.8%) and those undergoing noninvasive v

45 , 0.57 [95% CI, 0.40 to 0.81]), or requiring oxygen therapy (adjusted HR, 0.56 [95% CI, 0.38 to 0.81]

46 reduced the postmenstrual age at last use of oxygen therapy (adjusted mean difference, -0.8 weeks; 95

47 Our findings document that normobaric oxygen therapy administered during ischaemia nearly comp

48 est that conditioned high-flow nasal cannula oxygen therapy after extubation improves oxygenation com

49 in diaphragm thickening fraction, high-flow oxygen therapy allowed maintaining it unchanged, while i

50 o early noninvasive ventilation (n = 191) or oxygen therapy alone (n = 183).

51 early noninvasive ventilation compared with oxygen therapy alone did not reduce 28-day mortality.

52 l oxygen may be more effective than standard oxygen therapy alone in patients with acute hypoxemic re

53 associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (Pa

54 ith standard oxygen, compared with high-flow oxygen therapy and all noninvasive ventilation trials (p

55 decade have questioned the excessive use of oxygen therapy and have identified specific cardiovascul

56 s were evaluated: baseline with conventional oxygen therapy and high-flow nasal cannula at 20, 40, an

57 curred in 34 (34.3%) randomized to high-flow oxygen therapy and in 51 (51.0%) randomized to conventio

58 Infants with late PH had greater duration of oxygen therapy and increased mortality in the first year

59 a similar level of facilities (equipment for oxygen therapy and medications) and staffing (overall, o

60 sons), without differences between high-flow oxygen therapy and noninvasive ventilation.

61 ecessitating the institution of supplemental oxygen therapy and positive pressure mechanical ventilat

62 y rate, and patient comfort during high-flow oxygen therapy and standard oxygen at the time of noninv

63 easures, with the lowest rate for hyperbaric oxygen therapy and the highest for vertebroplasty.

64 asive ventilation over time, the duration of oxygen therapy and the rate of oxygen dependence at 36 w

65 n patients receiving modified nasopharyngeal oxygen therapy and those receiving high-flow nasal oxyge

66 therapy, and no difference between those on oxygen therapy and those without oxygen.

67 entional (n = 218) or conservative (n = 216) oxygen therapy and were included in the modified intent-

68 therapy by bubble CPAP, 67 (30%) to low-flow oxygen therapy, and 79 (35%) to high-flow oxygen therapy

69 e, extracorporeal life support or hyperbaric oxygen therapy, and animal studies.

70 scalation, intravenous fluid administration, oxygen therapy, and diagnostic tests were all increased

71 ally ill patients admitted to ICU, receiving oxygen therapy, and eligible for respiratory imaging wer

72 y syndrome coronavirus 2 infection, required oxygen therapy, and had adequate organ function.

73 up; and use of pulmonary hypertension drugs, oxygen therapy, and lower right atrial pressure, as well

74 ovision of appropriate antibiotics, standard oxygen therapy, and other supportive care.

75 sisted ventilation provided, the duration of oxygen therapy, and oxygen requirements at 36 weeks of a

76 bubble CPAP, 16 (24%) had received low-flow oxygen therapy, and ten (13%) had received high-flow oxy

77 er with the available literature, normobaric oxygen therapy appears a promising therapy for short-las

78 Among the advantages of high-flow oxygen therapy are comfort, availability, lower costs, a

79 Low birth weight and oxygen therapy are the most important risk factors for R

80 rom any cause or a requirement for long-term oxygen therapy as defined by the Nocturnal Oxygen Therap

81 tilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, d

82 ronic lung disease diagnosed by the need for oxygen therapy at a postmenstrual age of 36 weeks, need

83 those with comorbidity, and those who needed oxygen therapy at baseline.

84 to usual oxygen therapy (n = 8242) received oxygen therapy at the discretion of the treating clinici

85 Hyperbaric oxygen therapy (at 2.5 atmospheres absolute with 100% ox

86 ry low birth weight infants, associated with oxygen therapy, barotrauma, and/or infections.

87 ionale for clinical recommendations for home oxygen therapy based on scant empirical evidence, expert

88 and metabolic disturbance than does standard oxygen therapy but has no effect on short-term mortality

89 uces reintubation compared with conventional oxygen therapy, but not compared with noninvasive ventil

90 tion or mortality compared with conventional oxygen therapy, but there was no significant difference

91 domly allocated 79 (35%) children to receive oxygen therapy by bubble CPAP, 67 (30%) to low-flow oxyg

92 h severe pneumonia and hypoxaemia to receive oxygen therapy by either bubble CPAP (5 L/min starting a

93 ients (33.4%), mainly the need for prolonged oxygen therapy by nasal cannula (n = 235; 19.6%) and ate

94 ned as a requirement for hospitalization and oxygen therapy, (c) neurologic manifestations, and (d) a

95 piratory failure, the use of high-flow nasal oxygen therapy compared with intermittent BiPAP did not

96 e therapy compared with no therapy, and with oxygen therapy compared with no oxygen therapy.

97 ng-lasting sensorimotor deficits, normobaric oxygen therapy completely prevented sensorimotor deficit

98 Compared with liberal oxygen therapy, conservative oxygen therapy was not asso

99 ur capping trial plus intermittent high-flow oxygen therapy (control group) or to receive continuous

100 Patients received conventional oxygen therapy (COT) or HFNC (Optiflow, Fisher & Paykel,

101 ses in which a more conservative approach to oxygen therapy could be beneficial compared with a more

102 Use of bubble CPAP oxygen therapy could have a large effect in hospitals in

103 ed trial, patients were assigned to standard oxygen therapy, CPAP (5 to 15 cm of water), or NIPPV (in

104 ggestions of potential harm from unnecessary oxygen therapy, critically ill patients spend substantia

105 Conservative oxygen therapy decreased the median total amount of oxyg

106 We assessed whether oxygen therapy delivered by bubble continuous positive a

107 Oxygen therapy delivered by bubble CPAP improved outcome

108 randomly assigned to receive high-flow nasal oxygen therapy delivered continuously through a nasal ca

109 r less to high-flow oxygen therapy, standard oxygen therapy delivered through a face mask, or noninva

110 Importance: High-flow conditioned oxygen therapy delivered through nasal cannulae and noni

111 dmission diagnoses, pulse oximetry readings, oxygen therapy details, and final patient outcome.

112 imizing oxygen exposure through conservative oxygen therapy did not significantly reduce all-cause mo

113 ative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number

114 nasal cannula oxygen, compared with standard oxygen therapy, did not significantly reduce 28-day mort

115 improvement in the median time to sustained oxygen therapy discontinuation (5 vs 7 days) favoring bo

116 ia rely heavily on the level and duration of oxygen therapy, do not reflect contemporary neonatal car

117 rus coinfection (aOR, 1.4; 95% CI, 1.2-2.1), oxygen therapy during admission (aOR, 1.6; 95% CI, 1.1-2

118 f hospitalization, duration of symptoms, and oxygen therapy during admission, pneumococcal loads >/=1

119 time in the use of assisted ventilation and oxygen therapy during the newborn period and in lung fun

120 tegories: these included oxygen and reactive oxygen therapy; energy and radiation-based therapies; nu

121 increases in arterial O2 content, normobaric oxygen therapy experimentally induces significant increa

122 to undergo either high-flow or conventional oxygen therapy for 24 hours after extubation.

123 were randomly assigned to receive long-term oxygen therapy for 24 hours per day (117 patients) or 15

124 ed sooner (P=0.04) and received supplemental oxygen therapy for a shorter time (P=0.006).

125 ational study of patients starting long-term oxygen therapy for COPD in Sweden between 1 October 2005

126 anagement of hospitalized patients requiring oxygen therapy for moderate COVID-19.

127 verview of findings from clinical studies on oxygen therapy for myocardial ischaemia, cardiac arrest,

128 ; and (5) evaluate indications for long-term oxygen therapy for patients with COPD.

129 thy of prematurity is a major side effect of oxygen therapy for preterm infants, and is a leading cau

130 However, the efficacy of oxygen therapy for the management of isolated nocturnal

131 ion, monitoring, and discontinuation of home oxygen therapy for the pediatric population.

132 icoagulation for those with thromboembolism; oxygen therapy for those with low oxygen saturation; tre

133 rch 1 to April 15, 2020, receiving high-flow oxygen therapy (fraction of inspired oxygen, 50%).

134 h hyperinflammation and respiratory failure (oxygen therapy from 0.4 FiO(2) Venturi mask to invasive

135 protein >10 mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO(2) Venturi mask to invasive

136 Twenty-five patients in the conservative oxygen therapy group (11.6%) and 44 in the conventional

137 apy group (11.6%) and 44 in the conventional oxygen therapy group (20.2%) died during their ICU stay

138 ere randomly assigned to the high-flow nasal oxygen therapy group (Group HFNO) or the modified nasoph

139 (Group HFNO) or the modified nasopharyngeal oxygen therapy group (Group Naso).

140 p had treatment failure than in the low-flow oxygen therapy group (relative risk [RR] 0.27, 99.7% CI

141 n the bubble CPAP and those in the high-flow oxygen therapy group (RR 0.50, 99.7% 0.11-2.29; p=0.175)

142 % lower for participants in the conservative oxygen therapy group compared with the usual oxygen ther

143 Occurrences were lower in the conservative oxygen therapy group for new shock episode (ARR, 0.068 [

144 group and 31 of 144 (21.5%) in the standard oxygen therapy group had died (absolute difference, -6.5

145 908 participants (35.4%) in the conservative oxygen therapy group had died compared with 2858 (34.9%)

146 oup and in 66 of 145 (45.5%) in the standard oxygen therapy group within+ 7 days after randomization

147 he HFNO group, and 23.6% in the conventional oxygen therapy group).

148 11 in the conservative and 8183 in the usual oxygen therapy group).

149 oup, ten (15%) children died in the low-flow oxygen therapy group, and ten (13%) children died in the

150 and ten (13%) children died in the high-flow oxygen therapy group.

151 roup, and 13.9% (66/475) in the conventional oxygen therapy group.

152 died compared with 2858 (34.9%) in the usual oxygen therapy group.

153 oxygen therapy group compared with the usual oxygen therapy group.

154 ished to date, early-administered normobaric oxygen therapy had no significant effect on clinical out

155 sis of a nonrandomized comparison, long-term oxygen therapy has been recommended to be used for 24 ho

156 degree of systemic or local tissue hypoxia, oxygen therapy has been used liberally over many decades

157 Hyperbaric oxygen therapy has been used to treat a variety of ailme

158 and in 51 (51.0%) randomized to conventional oxygen therapy (hazard ratio, 0.62; 95% CI, 0.39-0.96; P

159 Hyperbaric oxygen therapy (HBOT) is a standard treatment, but its e

160 Hyperbaric oxygen therapy (HBOT) is proposed as treatment for late

161 Although evidence suggests that hyperbaric oxygen therapy (HBOT) may be beneficial, it is not widel

162 luate the ability of low-pressure hyperbaric oxygen therapy (HBOT) to improve behavioral and neurobio

163 addition to the above therapies, hyperbaric oxygen therapy (HBOT) was implemented as adjuvant treatm

164 use of racemic epinephrine, steroids, helium-oxygen therapy (heliox), or noninvasive positive pressur

165 therapy and those receiving high-flow nasal oxygen therapy (HFNO) following the induction of general

166 Compared with conventional oxygen therapy, high-flow nasal cannula decreased reintu

167 Home oxygen therapy (HOT) has been used to facilitate hospita

168 We evaluated the effects of hyperbaric oxygen therapy (HOT) on autoimmune diabetes development

169 derate certainty) compared with conventional oxygen therapy, however, certainty was limited by imprec

170 These include irradiation, hyperbaric oxygen therapy, hyper- or hypothermic therapy, and photo

171 Randomized Trial Comparing Two Approaches to Oxygen Therapy (ICU-ROX) trial.

172 High-flow oxygen therapy improved comfort, compared with standard

173 Oxygen therapy improves submaximal exercise tolerance in

174 Long-term oxygen therapy improves survival in patients with chroni

175 ide the basis for evidence-based use of home oxygen therapy in adults with COPD or ILD but also highl

176 nce and guidelines for the use of hyperbaric oxygen therapy in carbon monoxide-poisoned infants and c

177 dentified pertinent questions regarding home oxygen therapy in children, conducted systematic reviews

178 ical considerations in the use of hyperbaric oxygen therapy in children.

179 ught to determine the hemodynamic effects of oxygen therapy in heart failure.

180 immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.

181 Nasal high-flow oxygen therapy in infants with bronchiolitis and hypoxia

182 Conservative oxygen therapy in mechanically ventilated ICU patients w

183 n toxicity is the most severe side effect of oxygen therapy in neonates and adults.

184 provided conflicting data on the effects of oxygen therapy in normoxic cardiac patients.

185 factors contributing to CO2 retention due to oxygen therapy in patients with acute exacerbations of C

186 Clinicians should prescribe oxygen therapy in patients with COPD and resting hypoxem

187 that clinicians should prescribe continuous oxygen therapy in patients with COPD who have severe res

188 fect on survival or progression to long-term oxygen therapy in patients with COPD.

189 nale, evidence does not support supplemental oxygen therapy in patients with moderate resting or exer

190 Supplemental oxygen therapy in patients with ST-elevation-myocardial

191 The clinical effect of routine oxygen therapy in patients with suspected acute myocardi

192 Data strongly support supplemental oxygen therapy in people with severe resting desaturatio

193 findings support the use of high-flow nasal oxygen therapy in similar patients.

194 of carbon monoxide poisoning and hyperbaric oxygen therapy in the fetus, the newborn, the infant, an

195 the detrimental effects of excessive use of oxygen therapy, including the generation of toxic oxygen

196 he current evidence for the use of high-flow oxygen therapy, inhaled gases, and aerosols in the care

197 ilar effect size in settings where access to oxygen therapies is limited, this would translate into a

198 Oxygen therapy is a mainstay treatment for infants and a

199 Conservative oxygen therapy is aimed at the prevention of harm by iat

200 Although home oxygen therapy is commonly required in the care of child

201 Although oxygen therapy is essential, it contributes to disrupted

202 Supplemental oxygen therapy is frequently used in the treatment of pu

203 High-flow nasal oxygen therapy is increasingly used to improve oxygenati

204 Oxygen therapy is known to reduce loop gain (LG) in pati

205 Objective: To test if high-flow conditioned oxygen therapy is noninferior to NIV for preventing post

206 Home oxygen therapy is often required in children with chroni

207 Hyperbaric oxygen therapy is the administration of 100% oxygen at p

208 The goal of oxygen therapy is to deliver sufficient oxygen to the ti

209 ximeters in detecting hypoxaemia and guiding oxygen therapy is widely recognised, their role in prima

210 Palliative oxygen therapy is widely used for treatment of dyspnoea

211 Compared with conservative oxygen therapy, liberal oxygen therapy was not associate

212 Hyperbaric oxygen therapy may be helpful in preventing serious cent

213 High-flow conditioned oxygen therapy may offer advantages for these patients.

214 onchial artery re-anastomosis and hyperbaric oxygen therapy merit clinical investigation.

215 m of this report to emphasize the point that oxygen therapy might have major adverse physiologic effe

216 possible hospital cost-savings by targeting oxygen therapy might not be realized.

217 P (n = 380), HFNO (n = 418), or conventional oxygen therapy (n = 475).

218 ren were randomly allocated 1:1 to high-flow oxygen therapy (n = 753) or standard oxygen therapy (n =

219 gh-flow oxygen therapy (n = 753) or standard oxygen therapy (n = 764).

220 Participants randomized to usual oxygen therapy (n = 8242) received oxygen therapy at the

221 Participants randomized to conservative oxygen therapy (n = 8258) received the lowest fraction o

222 Any use of oxygen therapy, nasogastric-tube feeding, or ventilatory

223 Even with oxygen therapy, nearly half of CO poisoning survivors su

224 r rates of severe disease (80.8% vs. 63.4%), oxygen therapy need (80.8% vs. 63.4%), and longer hospit

225 frequent PPCs (eg, atelectasis and prolonged oxygen therapy need) deserve increased attention and int

226 After 3 months of oxygen therapy, nine of nine eyes with DME at baseline s

227 enstrual age, regardless of prior or current oxygen therapy: no bronchopulmonary dysplasia, no suppor

228 immunoglobulin (IVIG) as well as hyperbaric oxygen therapy, none have been the complete answer.

229 As compared with standard oxygen therapy, noninvasive ventilation was associated w

230 Preterm infants requiring prolonged oxygen therapy often develop cognitive dysfunction in la

231 Nevertheless, the effects of normobaric oxygen therapy on infarct volume in rodent models have b

232 ered after brief assessment of the effect of oxygen therapy on the individual patient.

233 or osteoporotic spinal fractures, hyperbaric oxygen therapy, oophorectomy with hysterectomy, and lapa

234 met the NOTT-defined criteria for long-term oxygen therapy or had died (difference, -3.0 percentage

235 Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ven

236 y developed to predict the risk of high-flow oxygen therapy or mechanical ventilation requirement dur

237 ized to undergo either high-flow conditioned oxygen therapy or NIV for 24 hours after extubation.

238 cannulae with usual care (i.e., conventional oxygen therapy or noninvasive ventilation) in adults wit

239 re successfully weaned from HFNC to low-flow oxygen therapy or room air, 431 (1.6%) were restarted on

240 or 12) to receive treatment with hyperbaric oxygen therapy or sham.

241 tandard oxygen, compared with both high-flow oxygen therapy (p < 0.001) and noninvasive ventilation (

242 h standard oxygen (p <= 0.005) and high-flow oxygen therapy (p <= 0.001).

243 There were no differences in duration of oxygen therapy (p = 0.74) or time to resolution of sympt

244 volume ventilation, use of caffeine therapy, oxygen therapy post-surfactant and increasing early use

245 ed that low BW and GA; prolonged duration of oxygen therapy; presence of PDA and necrotizing enteroco

246 ere we tested the hypothesis that normobaric oxygen therapy prevents both selective neuronal loss and

247 adding home noninvasive ventilation to home oxygen therapy prolonged the time to readmission or deat

248 ctioning frequency plus continuous high-flow oxygen therapy rather than on 24-hour capping trials plu

249 g intermediate-high risk pulmonary embolism, oxygen therapy reduced right ventricle afterload and low

250 al cannula oxygen compared with conventional oxygen therapy reduced the risk of reintubation within 7

251 l surgery, use of NIV compared with standard oxygen therapy reduced the risk of tracheal reintubation

252 r capping trials plus intermittent high-flow oxygen therapy reduced the time to decannulation, with n

253 the children who received oxygen by low-flow oxygen therapy (RR 0.25, 95% CI 0.07-0.89; p=0.022).

254 3.9; 95% CI, 3.4-4.5), need for supplemental oxygen therapy (RR, 3.4; 95% CI, .5-21.1), and need for

255 endations were developed for or against home oxygen therapy specific to pediatric lung and pulmonary

256 red oxygen of 300 mm Hg or less to high-flow oxygen therapy, standard oxygen therapy delivered throug

257 Rationale: Aerosol generation with modes of oxygen therapy such as high-flow nasal cannula and nonin

258 nts with ARDS to receive either conservative oxygen therapy (target Pao(2), 55 to 70 mm Hg; oxygen sa

259 lse oximetry [Spo(2)], 88 to 92%) or liberal oxygen therapy (target Pao(2), 90 to 105 mm Hg; Spo(2),

260 Implementation of a conservative approach to oxygen therapy (target SpO2 of 90-92%).

261 at least 0.50 in a closed system to receive oxygen therapy targeting a Pao(2) of either 60 mm Hg (lo

262 that can be used regardless of the level of oxygen therapy that a patient is already receiving.

263 During conservative oxygen therapy the median time-weighted average SpO2 on

264 With fluid resuscitation and oxygen therapy, the patient regained consciousness after

265 2 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask.

266 2 mm Hg and pulse oximetry of 93% on 6 L/min oxygen therapy through a nonrebreathing mask.

267 s based on RT-PCR, COVID-19 contact history, oxygen therapy, timing of RT-PCR testing, and likely alt

268 clinical studies suggesting that keeping the oxygen therapy to an "acceptable" minimum in premature b

269 es are needed for effective delivery of home oxygen therapy to appropriate patients with chronic obst

270 : Patients were randomly assigned to receive oxygen therapy to maintain Pao2 between 70 and 100 mm Hg

271 rations can have a valuable role in bringing oxygen therapy to patients and hospitals in countries wh

272 m oxygen therapy as defined by the Nocturnal Oxygen Therapy Trial (NOTT) criteria in the intention-to

273 s were randomly assigned to receive standard oxygen therapy (up to 15 L/min to maintain SpO2 of 94% o

274 variates included age, body mass index, home oxygen therapy use, respiratory rate, heart rate, oxygen

275 ng patients with severe hypoxemia, long-term oxygen therapy used for 24 hours per day did not result

276 tibiotics, intravenous fluid administration, oxygen therapy, vasopressors, and diagnostic tests.

277 hours or longer, a conservative protocol for oxygen therapy vs conventional therapy resulted in lower

278 The median duration of oxygen therapy was 11.6 hours, and the median oxygen sat

279 he median patient-reported daily duration of oxygen therapy was 24.0 hours (interquartile range, 21.0

280 Oxygen therapy was advised in 133 patients.

281 Normobaric oxygen therapy was applied from the onset and until comp

282 xygenation strategies compared with standard oxygen therapy was associated with lower risk of death.

283 between noninvasive ventilation and standard oxygen therapy was death within 7 days after the initiat

284 Of patients with hypoxaemia, oxygen therapy was documented for 88% (79-97) of neonate

285 assess whether routine prophylactic low-dose oxygen therapy was more effective than control oxygen ad

286 ed with liberal oxygen therapy, conservative oxygen therapy was not associated with decreased mortali

287 ed with conservative oxygen therapy, liberal oxygen therapy was not associated with increased mortali

288 High-flow nasal oxygen therapy was not inferior to BiPAP: the treatment

289 undergone extubation, high-flow conditioned oxygen therapy was not inferior to NIV for preventing re

290 s prescribed for 75% of patients, hyperbaric oxygen therapy was prescribed for 43.8% of patients, and

291 esaturation without qualifying for long-term oxygen therapy, whether nocturnal oxygen provided for a

292 Modified nasopharyngeal oxygen therapy which uses far less oxygen than HFNO is a

293 on noninvasive therapy and 4 mins post-100% oxygen therapy with a bag-mask assembly.

294 s of active preoxygenation efforts with 100% oxygen therapy with a noncollapsing resuscitator bag and

295 nclusions were drawn that the need for early oxygen therapy with an oxygen mask and low pH values in

296 9, 95% CI 1.4 to 746, P = 0.03) and need for oxygen therapy with C4d (11.7, 1.1 to 130, P = 0.045).

297 ol group) or to receive continuous high-flow oxygen therapy with frequency of suctioning being the in

298 , there is a wide variation in approaches to oxygen therapy within neonatal intensive care units.

299 Simulation results with an oxygen therapy within the unstable time-window demonstra

300 Noninferiority of high-flow nasal oxygen therapy would be demonstrated if the lower bounda